Research
Hormonal
GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.
GLP-1 RA may help improve glycemic control in LVAD patients.
StrongSupportsmedium confidence
HBA1C was improved (6.4 (5.8-8.1) vs. 5.7 (5.3-6.1), p-value 0.003).
Why this rating
Based on a retrospective analysis of patient outcomes.
Source
Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices
B. Elad et al. · Artificial Organs · 2025
DOI 10.1111/aor.14942
cohort · n=40Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →